These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

834 related articles for article (PubMed ID: 25538019)

  • 21. A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group study.
    Cardenes HR; Moore AM; Johnson CS; Yu M; Helft P; Chiorean EG; Vinson J; Howard TJ; Stephens AW; Tai DF; Loehrer PJ
    Am J Clin Oncol; 2011 Oct; 34(5):460-5. PubMed ID: 20881474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stereotactic body radiation therapy for locally advanced pancreatic cancer.
    Jung J; Yoon SM; Park JH; Seo DW; Lee SS; Kim MH; Lee SK; Park DH; Song TJ; Ryoo BY; Chang HM; Kim KP; Yoo C; Jeong JH; Kim SC; Hwang DW; Lee JH; Song KB; Jo YY; Park J; Kim JH
    PLoS One; 2019; 14(4):e0214970. PubMed ID: 30978229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).
    Gao S; Zhu X; Shi X; Cao K; Bian Y; Jiang H; Wang K; Guo S; Zhang H; Jin G
    Radiat Oncol; 2019 Mar; 14(1):52. PubMed ID: 30917842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I Trial of Stereotactic Body Radiation Therapy Dose Escalation in Pancreatic Cancer.
    Courtney PT; Paravati AJ; Atwood TF; Raja N; Zimmerman CT; Fanta PT; Lowy AM; Simpson DR; Xu R; Murphy JD
    Int J Radiat Oncol Biol Phys; 2021 Jul; 110(4):1003-1012. PubMed ID: 33571625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Linac-based stereotactic body radiation therapy for unresectable locally advanced pancreatic cancer: risk-adapted dose prescription and image-guided delivery.
    Mazzola R; Fersino S; Aiello D; Gregucci F; Tebano U; Corradini S; Di Paola G; Cirillo M; Tondulli L; Ruffo G; Ruggieri R; Alongi F
    Strahlenther Onkol; 2018 Sep; 194(9):835-842. PubMed ID: 29696321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.
    Lin C; Verma V; Ly QP; Lazenby A; Sasson A; Schwarz JK; Meza JL; Are C; Li S; Wang S; Hahn SM; Grem JL
    Radiother Oncol; 2019 Mar; 132():55-62. PubMed ID: 30825970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of gemcitabine chemotherapy and 3-dimensional conformal radiation therapy/5-fluorouracil on quality of life of patients managed for pancreatic cancer.
    Short M; Goldstein D; Halkett G; Reece W; Borg M; Zissiadis Y; Kneebone A; Spry N
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):157-62. PubMed ID: 22543205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma.
    Lin C; Verma V; Lazenby A; Ly QP; Berim LD; Schwarz JK; Madiyalakan M; Nicodemus CF; Hollingsworth MA; Meza JL; Are C; Padussis J; Grem JL
    Am J Clin Oncol; 2019 Oct; 42(10):755-760. PubMed ID: 31513018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.
    Park JJ; Hajj C; Reyngold M; Shi W; Zhang Z; Cuaron JJ; Crane CH; O'Reilly EM; Lowery MA; Yu KH; Goodman KA; Wu AJ
    Acta Oncol; 2017 Dec; 56(12):1746-1753. PubMed ID: 28661823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.
    Chuong MD; Springett GM; Freilich JM; Park CK; Weber JM; Mellon EA; Hodul PJ; Malafa MP; Meredith KL; Hoffe SE; Shridhar R
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):516-22. PubMed ID: 23562768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation.
    Zhong J; Patel K; Switchenko J; Cassidy RJ; Hall WA; Gillespie T; Patel PR; Kooby D; Landry J
    Cancer; 2017 Sep; 123(18):3486-3493. PubMed ID: 28493288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma.
    Gurka MK; Kim C; He AR; Charabaty A; Haddad N; Turocy J; Johnson L; Jackson P; Weiner LM; Marshall JL; Collins SP; Pishvaian MJ; Unger K
    Am J Clin Oncol; 2017 Apr; 40(2):152-157. PubMed ID: 25171298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer.
    Rajagopalan MS; Heron DE; Wegner RE; Zeh HJ; Bahary N; Krasinskas AM; Lembersky B; Brand R; Moser AJ; Quinn AE; Burton SA
    Radiat Oncol; 2013 Oct; 8():254. PubMed ID: 24175982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantification of renal function following stereotactic body radiotherapy for pancreatic cancer: secondary dosimetric analysis of a prospective clinical trial.
    Verma V; Bhirud AR; Denniston KA; Bennion NR; Lin C
    Radiat Oncol; 2017 Apr; 12(1):71. PubMed ID: 28449702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine.
    Baschnagel A; Shah C; Margolis J; Nadeau L; Stein J; Jury R; Robertson JM
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e331-5. PubMed ID: 22420967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma.
    Van Buren G; Ramanathan RK; Krasinskas AM; Smith RP; Abood GJ; Bahary N; Lembersky BC; Shuai Y; Potter DM; Bartlett DL; Zureikat AH; Zeh HJ; Moser AJ
    Ann Surg Oncol; 2013 Nov; 20(12):3787-93. PubMed ID: 23904005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
    Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
    Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003.
    Mamon HJ; Niedzwiecki D; Hollis D; Tan BR; Mayer RJ; Tepper JE; Goldberg RM; Blackstock AW; Fuchs CS;
    Cancer; 2011 Jun; 117(12):2620-8. PubMed ID: 21656739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience.
    Polistina FA; Guglielmi R; Baiocchi C; Francescon P; Scalchi P; Febbraro A; Costantin G; Ambrosino G
    Radiother Oncol; 2011 May; 99(2):120-3. PubMed ID: 21621289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas.
    Chang DT; Schellenberg D; Shen J; Kim J; Goodman KA; Fisher GA; Ford JM; Desser T; Quon A; Koong AC
    Cancer; 2009 Feb; 115(3):665-72. PubMed ID: 19117351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.